Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Global Blood Ther (GBT)

Global Blood Ther (GBT)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
68.49 +0.01 (+0.01%) 10/04/22 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 68.49 unch (unch) -
Quote Overview for Tue, Oct 4th, 2022
Day Low
68.47
Day High
68.49
Open 68.48
Previous Close 68.48 68.48
Volume 3,279,900 3,279,900
Avg Vol 2,771,555 2,771,555
Stochastic %K 91.89% 91.89%
Weighted Alpha +51.60 +51.60
5-Day Change +0.31 (+0.45%) +0.31 (+0.45%)
52-Week Range 21.65 - 73.02 21.65 - 73.02
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,621,431
  • Shares Outstanding, K 67,476
  • Annual Sales, $ 194,750 K
  • Annual Income, $ -303,090 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 0.45
  • Price/Sales 23.73
  • Price/Cash Flow N/A
  • Price/Book 37.67
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -5.01
  • Most Recent Earnings $-1.26 on 08/08/22
  • Next Earnings Date 11/03/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -1.16
  • Number of Estimates 15
  • High Estimate -0.95
  • Low Estimate -1.51
  • Prior Year -1.13
  • Growth Rate Est. (year over year) -2.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
67.54 +1.41%
on 09/16/22
Period Open: 67.80
68.49 unch
on 10/04/22
+0.69 (+1.02%)
since 09/02/22
3-Month
31.51 +117.36%
on 08/01/22
Period Open: 32.80
73.02 -6.20%
on 08/05/22
+35.69 (+108.81%)
since 07/01/22
52-Week
21.65 +216.35%
on 06/13/22
Period Open: 26.12
73.02 -6.20%
on 08/05/22
+42.37 (+162.21%)
since 10/04/21

Most Recent Stories

More News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MNRL, STOR, GBT, IRBT

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

MNRL : 32.50 (-1.57%)
STOR : 32.21 (unch)
GBT : 68.49 (+0.01%)
IRBT : 2.09 (+1.95%)
INVESTIGATION ALERT: Halper Sadeh LLC Investigates FBMS, GBT, MVBF

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

FBMS : 33.81 (+0.48%)
GBT : 68.49 (+0.01%)
MVBF : 15.88 (-1.67%)
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBT

/PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

FTAI : 98.92 (+2.58%)
SBTX : 5.87 (+1.03%)
CVET : 20.99 (+0.29%)
GBT : 68.49 (+0.01%)
SHAREHOLDER ALERT: Weiss Law Reminds SBTX, CVET, GBT, and MSTR Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

SBTX : 5.87 (+1.03%)
CVET : 20.99 (+0.29%)
GBT : 68.49 (+0.01%)
MSTR : 299.98 (+10.15%)
GLOBAL BLOOD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Global Blood Therapeutics, Inc. - GBT

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Global Blood Therapeutics, Inc. (GBT) (NasdaqGS:...

GBT : 68.49 (+0.01%)
PFE : 21.91 (+1.48%)
SHAREHOLDER ALERT: Weiss Law Reminds LTRY, MSTR, GBT, and PFHD Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

LTRY : 0.8041 (-4.85%)
MSTR : 299.98 (+10.15%)
GBT : 68.49 (+0.01%)
PFHD : 28.65 (-0.52%)
SHAREHOLDER ALERT: Weiss Law Reminds CYBE, GBT, PFHD, and BBQ Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

CYBE : 54.00 (unch)
GBT : 68.49 (+0.01%)
PFHD : 28.65 (-0.52%)
BBQ : 17.24 (unch)
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates AAWW, GBT, CYBE, AVLR

/PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

AAWW : 102.48 (+0.02%)
GBT : 68.49 (+0.01%)
CYBE : 54.00 (unch)
AVLR : 93.48 (+0.03%)
SHAREHOLDER ALERT: Weiss Law Reminds AVLR, CYBE, GBT, and PFHD Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

AVLR : 93.48 (+0.03%)
CYBE : 54.00 (unch)
GBT : 68.49 (+0.01%)
PFHD : 28.65 (-0.52%)
GLOBAL BLOOD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Global Blood Therapeutics, Inc. - GBT

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Global Blood Therapeutics, Inc. (GBT) (NasdaqGS:...

GBT : 68.49 (+0.01%)
PFE : 21.91 (+1.48%)
Viatris, First Solar rise; Tyson Foods, Nvidia fall

NEW YORK (AP) — Stocks that traded heavily or had substantial price changes Monday:

FSLR : 125.93 (+3.06%)
THS : 23.30 (+7.62%)
KRTX : 329.83 (+0.03%)
BNTX : 96.52 (+3.65%)
GBT : 68.49 (+0.01%)
PFE : 21.91 (+1.48%)
TSN : 60.54 (+0.68%)
NVDA : 110.93 (+3.12%)
SHAREHOLDER ALERT: Weiss Law Investigates Global Blood Therapeutics, Inc.

/PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Global Blood...

GBT : 68.49 (+0.01%)
PFE : 21.91 (+1.48%)
Why Global Blood Therapeutics Stock Was Trouncing the Market Today

The blood-disorder specialist sells itself in a deal with an enterprise value of around $5.4 billion.

GBT : 68.49 (+0.01%)
PFE : 21.91 (+1.48%)
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates GBT, AVLR, CYBE

/PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

GBT : 68.49 (+0.01%)
AVLR : 93.48 (+0.03%)
CYBE : 54.00 (unch)
Pfizer buying spree continues with $5.4B hematology deal

Pfizer will spend about $5.4 billion to buy Global Blood Therapeutics as the pharmaceutical giant continues to invest some of the cash influx reaped during the COVID-19 pandemic.

$SPX : 5,363.36 (+1.81%)
$DOWI : 40,212.71 (+1.56%)
$IUXX : 18,690.05 (+1.89%)
PFE : 21.91 (+1.48%)
GBT : 68.49 (+0.01%)
Global Blood (GBT) Stock Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Global Blood Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – GBT

Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Global Blood Therapeutics, Inc. (NASDAQ: GBT) to Pfizer Inc. for $68.50 per share in cash is fair to Global Blood...

GBT : 68.49 (+0.01%)
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology

Pfizer Inc. (NYSE: PFE) and Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT, a biopharmaceutical...

PFE : 21.91 (+1.48%)
GBT : 68.49 (+0.01%)
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology

Proposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio and pipeline to Pfizer with potential combined worldwide...

GBT : 68.49 (+0.01%)
Why Global Blood Therapeutics Stock Is Vaulting Higher Today

Pfizer emerges as the lead suitor for the rare-disease company.

GBT : 68.49 (+0.01%)
PFE : 21.91 (+1.48%)
Why Global Blood Therapeutics Stock Is Soaring Today

A buyout rumor is powering the biotech's shares higher.

GBT : 68.49 (+0.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops treatments for underserved patient communities.

See More

Key Turning Points

3rd Resistance Point 68.52
2nd Resistance Point 68.50
1st Resistance Point 68.50
Last Price 68.49
1st Support Level 68.48
2nd Support Level 68.46
3rd Support Level 68.46

See More

52-Week High 73.02
Last Price 68.49
Fibonacci 61.8% 53.40
Fibonacci 50% 47.33
Fibonacci 38.2% 41.27
52-Week Low 21.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar